You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The Phase 0 trial will assess whether infigratinib can cross the blood-brain barrier to penetrate recurrent high-grade gliomas harboring FGFR genetic alterations.
Use of the drug resulted in an encouraging response when an infant patient received it off-label in a first-line setting.
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
Glioma patients experienced tumors shrinkage, and some AML patients had a complete remission that allowed them to proceed to curative treatment.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
Based on the finding that 80 percent of low-grade glioma patients saw their tumors shrink, researchers suggested that BRAF inhibitors may be useful in earlier lines of treatment.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
The trial will evaluate the effects of the single agent ONC201 in patients who have recurrent high-grade gliomas with low EGFR expression.
A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.
The FDA and its pediatric oncology drugs advisory committee heard at a recent meeting how the drug is allowing some to live longer than expected, without toxicities.